National Psoriasis Foundation

Clinical Trials

Find a trial

Reasons to participate

  • Access to new treatments not available on the market.
  • Access to free medication.
  • Compensation for participating (in some trials).
  • Satisifcation in helping advance medical research.

Factors to consider

It's important to check with your health care provider to determine if participating in a clinical trial is right for you. Learn more about clinical trials, what questions to ask before participating and the drug approval process.

Sponsored Studies

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients.

Condition: Chronic Plaque-type Psoriasis | Phase: Phase 1/Phase 2 | Minimum Age: 18 Years

Learn more »

T and B Cell Responses in Autoimmune Diseases

The study aims to establish whether defects in immune cell function are shared across multiple autoimmune diseases and whether those problems match to similar genes in the cells.

Condition: Type 1 Diabetes Mellitus | Phase: N/A | Minimum Age: 8 Years

Learn more »

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.

Condition: Psoriasis | Phase: Phase 3 | Minimum Age: 18 Years

Learn more »

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

Psoriatic arthritis is a heterogeneous chronic inflammatory disorder involving joints, tendon sheaths, entheses, and the axial skeleton as well as skin and nails. This is an open-label trial with H.P. Acthar Gel (80 units/1mL) Subcutaneous injection administered twice weekly. To evaluate the signs and symptoms of psoriatic arthritis after 12 weeks, including American College of Rheumatology 20,Clinical Disease Activity Index, Disease Activity Index 28, Dactylitis and adverse events.

Condition: Psoriatic Arthritis | Phase: Phase 4 | Minimum Age: 18 Years

Learn more »

Study of of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy

This study is being done to evaluate the safety, tolerability, activity, pharmacokinetics (PK), and daily dose regimen of KD025 administered orally for 12 weeks to subjects with psoriasis vulgaris who have failed at least one line of systemic therapy.

Condition: Psoriasis Vulgaris | Phase: Phase 2 | Minimum Age: 18 Years

Learn more »

Get the latest research news and tips on managing your psoriasis and psoriatic arthritis.